Table 1.

General information at each phase of data collection.

Study component		Phase 1 (N=308)	Phase 2 (n=185)	Phase 3 (n=148)
Design		Prospective	Prospective	Cross-sectional and retrospective
Study visits		Routine clinical evaluation every 3 months; virological data collected every 6 months; fibrosis or serological data collected every 12 months	Routine clinical evaluation and data collection every 6 and 12 months for participants with F3/F4 and F0/F1/F2 fibrosis, respectivelya	Cross-sectional visit including comprehensive clinical evaluation on viral hepatitis and liver fibrosis; retrospective data collected since last visit in phase 1 or 2
Inclusion period		2002-2003	2007-2008	2016-2018
Follow-up period		2002-2006	2007-2011	N/Ab
Number of patients completing follow-up, n (%)		275 (89.3)	163 (88.1)	147 (99.3)
Number of deaths
	Total	3	8	31
	Observed	3	6c	26c
	Updatedd	0	2	5
Follow-up time (years), median (IQR)		3.0 (3.0-3.2)	7.3 (3.1-8.0)e	9.2 (3.4-14.6)e

^aIn accordance with the European AIDS Clinical Society guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in adults with HIV [18].

^bN/A: not applicable.

^cIncludes deaths during time gaps in between phases.

^dUsing linked data from a national death certificate registry (CépiDC).

^eCumulated over previous phases—this statistic applies to all 308 patients regardless of the phase in which they discontinued participation.